This is a speculative early-stage pipeline update from a micro-cap biotech with no new clinical data or partnership. Traders should watch for any out-licensing agreement or IND filing as the next catalyst; absent that, the stock is likely to remain range-bound with low volume.
Price Chart
Executive Summary
Galmed Pharmaceuticals announced preclinical progress on an orally dispersible film (ODF) formulation of its SCD1 inhibitor Aramchol for Parkinson's disease, reporting ~150% higher systemic bioavailability and ~300% greater CNS exposure versus conventional oral administration. The press release targets the $6B+ Parkinson's therapeutics market and positions the program for out-licensing, but no new clinical trial data, regulatory milestones, or financial terms were disclosed. This is an early-stage, non-clinical update from a micro-cap company with a $4M market cap, making the announcement speculative with no near-term revenue or catalyst certainty.
Key Facts
- Galmed announced an ODF formulation of Aramchol for Parkinson's disease with ~150% higher systemic bioavailability and ~300% greater CNS exposure vs. conventional oral administration.
- The press release targets the $6+ billion global Parkinson's therapeutics market and describes the program as an 'ideal out-licensing candidate.'
- No new clinical trial data, regulatory filings, or partnership agreements were disclosed; the data are preclinical/formulation development.
- Galmed has a $4M market cap and 0% analyst bullish consensus (0 Buy, 3 Hold, 3 Sell/Strong Sell).
Financial Impact
No financial figures disclosed; the press release references a $6+ billion addressable market but provides no deal value, revenue, or funding commitment.
Risk Factors
- No clinical data in Parkinson's patients — all results are preclinical/formulation pharmacokinetic comparisons.
- Galmed has a $4M market cap and negative analyst sentiment (0% bullish), indicating limited institutional interest and high dilution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-034933 |
| Document: form6-k.htm | 0001493152-26-034933 |
| Document: 0001493152-26-034933-index-headers.html | 0001493152-26-034933 |
| Document: 0001493152-26-034933-index.html | 0001493152-26-034933 |
| Document: 0001493152-26-034933.txt | 0001493152-26-034933 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 6-K | $4.63 $3.63 | ▼ −21.71% | ▼ −21.37% | — |
Sep 4, 2026 7w ago | EFFECT | $3.88 $4.63 | ▼ −19.33% | ▼ −20.54% | — |
Sep 3, 2026 7w ago | 6-K | $3.88 $4.63 | ▲ +19.33% | ▲ +20.54% | — |
Sep 2, 2026 7w ago | 6-K | $3.92 $4.63 | ▲ +18.11% | ▲ +19.26% | — |
Aug 19, 2026 9w ago | 6-K | $4.77 $4.33 | ▼ −9.22% | ▼ −8.84% | — |
Aug 17, 2026 10w ago | 6-K | $0.5134 | awaiting T+5 | — | — |
Jul 28, 2026 13w ago | 6-K | $0.5340 $0.5754 | ▲ +7.75% | ▲ +3.64% | — |
Jul 16, 2026 14w ago | 6-K | $0.5501 $0.5530 | ▲ +0.53% | ▲ +2.20% | — |
Jun 22, 2026 18w ago | 6-K | $0.5641 $0.5709 | ▲ +1.21% | ▲ +1.66% | — |
Jun 8, 2026 20w ago | 6-K | $0.4693 $0.6160 | ▲ +31.26% | ▲ +29.15% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers